SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash

SpyGlass Pharma, Inc. has acquired Advanced Vision Science, Inc. (AVS) for approximately $13 million in cash. This acquisition secures scalable manufacturing capacity for SpyGlass's Phase 3 BIM-IOL System and allows for the addition of premium lens options. AVS, previously a subsidiary of Santen Pharmaceutical Co., will continue to supply various IOLs to Santen for commercialization in Japan and license its lens material technology to Bausch + Lomb and other companies.